Can I Switch From Metoprolol Tartrate to Succinate?

Switching from metoprolol tartrate to metoprolol succinate is a common and generally straightforward medication change, but it requires your prescriber’s involvement because the two formulations behave differently in your body. Both contain the same active drug, metoprolol, a beta-blocker used for high blood pressure, chest pain, heart failure, and heart rhythm problems. The critical difference is how each version releases metoprolol into your bloodstream, and that difference affects dosing, how often you take it, and in some clinical scenarios, how well it works.

Why the Two Formulations Are Not Interchangeable by Default

Metoprolol tartrate is an immediate-release tablet, usually taken twice a day. Metoprolol succinate is an extended-release tablet designed to be taken once a day. Because the extended-release version delivers metoprolol slowly and steadily, it produces lower peak drug levels in the blood while maintaining higher levels toward the end of the dosing period compared to the immediate-release form.¹ That smoother drug-level curve means more consistent beta-blockade across a full 24-hour day, rather than the peaks and valleys you get with a twice-daily immediate-release dose.

The extended-release formulation also has roughly 20% lower overall bioavailability compared to immediate-release metoprolol, meaning your body absorbs somewhat less of the total drug from the same milligram dose.² This is one reason you cannot simply swap milligram-for-milligram without thinking about it. Your doctor will account for the bioavailability difference and the change in dosing frequency when calculating your new dose.

How Dose Conversion Typically Works

The most common conversion approach is to match the total daily dose of metoprolol tartrate with an equivalent dose of metoprolol succinate, then give it as a single daily dose. If you take 50 mg of tartrate twice a day (100 mg total), your doctor will often start you on 100 mg of succinate once daily. For someone on tartrate three times daily at higher doses, the succinate dose is consolidated the same way.

This approach works in practice because while the extended-release version has slightly lower bioavailability per milligram, the sustained drug levels throughout the day tend to compensate. In the landmark heart failure trial MERIT-HF, researchers noted that the succinate formulation could achieve more even beta-blockade over 24 hours at a target dose of 200 mg once daily, compared to 50 mg of the immediate-release form taken three times a day, without increasing peak drug concentrations.³ Your prescriber may adjust the dose up or down after the switch based on your blood pressure and heart rate response.

When and Why Your Doctor Might Recommend Switching

There are several practical and clinical reasons a switch gets recommended. The most common is simply convenience: going from two pills a day to one. But for certain conditions, the formulation itself matters more than you might expect.

In heart failure with reduced pumping ability, the evidence strongly favors the succinate formulation. A large multicenter study found that patients on succinate had meaningfully better event-free survival than those on tartrate, with the benefit showing up in both fewer hospitalizations and lower overall death rates.⁴ Current heart failure guidelines specifically recommend metoprolol succinate, not tartrate, as one of the evidence-based beta-blockers for this condition. If you have heart failure and are on tartrate, your cardiologist has good reason to switch you.

For high blood pressure without heart failure, the picture is less dramatic but still tilts toward succinate. A systematic review found that blood pressure normalized in about 69% of patients on succinate versus about 63% on tartrate, with a better safety profile for the extended-release form.⁵ Part of this advantage comes from the sustained drug levels: the controlled-release form produces a greater reduction in heart rate at the 24-hour mark, meaning it is still working strongly at the end of the dose interval when the immediate-release version may be wearing off.⁶

For conditions like atrial fibrillation or other heart rhythm issues where beta-blocker coverage throughout the day matters, the logic is similar. When both formulations were compared head-to-head in heart failure patients over a longer period, their effects on exercise capacity, cardiac output, and blood vessel resistance were essentially the same, suggesting that when the total daily dose is matched, neither formulation is pharmacologically “stronger” than the other.⁷ The succinate version simply provides more consistent coverage.

The Adherence Advantage of Once-Daily Dosing

This is one of the strongest practical arguments for switching, and it is easy to underestimate. A meta-analysis of cardiovascular medication adherence found that people taking pills twice daily had adherence rates roughly 14 percentage points lower than those on once-daily regimens.⁸ That gap is significant in real-world terms. Missing doses of a beta-blocker is not the same as forgetting a vitamin. With metoprolol, skipped or late doses can leave you exposed to blood pressure spikes and heart rate increases, and inconsistent dosing over time erodes the cardiac protection the drug is supposed to provide.

If you find yourself regularly missing the second dose of tartrate, especially the evening dose, that alone may be a good reason to discuss switching. Many people find the once-daily succinate version much easier to build into a morning routine.

What to Watch for During and After the Switch

The transition itself is usually done in one step: you stop tartrate and start succinate the next day at the equivalent daily dose. There is no need for a tapering period between the two because you are not stopping metoprolol, just changing the delivery system. However, your doctor may want to check your heart rate and blood pressure within the first week or two, especially if your dose is being adjusted at the same time.

The main safety concern during any beta-blocker transition is avoiding an accidental gap in therapy. Abrupt withdrawal of metoprolol can trigger a rebound increase in heart rate, with studies documenting an average resting heart rate rise of about 15% within two to eight days of sudden discontinuation.⁹ In people with underlying heart disease, this rebound can be more dangerous, and case reports document hypertensive crises when metoprolol and other drugs were stopped abruptly at the same time.¹⁰ Even gradual withdrawal of metoprolol has been associated with a rebound increase in heart rate lasting up to three weeks.¹¹

The practical takeaway: do not let your prescription lapse between formulations. If your pharmacy has trouble filling the new prescription, keep taking the old one until you can pick up the new version. Do not stop both and wait.

Why You Should Not Crush or Split Succinate Tablets

This trips people up, especially those switching from tartrate. Metoprolol tartrate is a simple immediate-release pill. You can split it in half if needed, and it still works normally. Metoprolol succinate is a completely different engineering feat. Each tablet contains hundreds of tiny controlled-release pellets, and each pellet is designed to release metoprolol slowly on its own.¹² When you split a succinate tablet, the pellets are not distributed evenly between the two halves, so one half may contain substantially more drug than the other. Crushing the tablet is worse: it destroys the controlled-release mechanism entirely and turns an extended-release dose into an immediate-release dump, which could produce dangerously high peak levels.

If you need a dose that does not come in a standard tablet size, talk to your pharmacist about available strengths rather than splitting. Metoprolol succinate comes in 25 mg, 50 mg, 100 mg, and 200 mg tablets, which covers most dose steps.

How Your Genetics Can Affect the Switch

Metoprolol is broken down in the liver primarily by an enzyme called CYP2D6. People vary considerably in how active this enzyme is, and those differences are largely genetic. Research has shown that people with lower CYP2D6 activity clear metoprolol from their blood more slowly, resulting in higher drug levels at any given dose.¹³ This matters for both tartrate and succinate, but it becomes especially relevant during a switch because any dose adjustment may produce an unexpectedly large or small effect depending on your metabolizer status.

About 5–10% of people of European descent are poor metabolizers of CYP2D6, meaning they break down metoprolol very slowly and may experience stronger effects, including lower heart rate and blood pressure, from a standard dose. In hospitalized patients treated for heart attacks, CYP2D6 genotype was a major determinant of how much metoprolol ended up in the blood.¹⁴ If you have ever been told you are a slow metabolizer, or if you have had unusual sensitivity to metoprolol at standard doses, mention that to your doctor before switching formulations.

Drug Interactions That Complicate the Picture

The CYP2D6 enzyme that metabolizes metoprolol can be blocked by certain common medications, effectively turning a normal metabolizer into a slow one. The most clinically relevant examples are the antidepressants paroxetine and fluoxetine. Studies have found that paroxetine increases metoprolol blood levels by three to five times, with measurable drops in blood pressure and heart rate, and case reports have documented serious slowing of the heart as a result.¹⁵ If you take either of these antidepressants and are switching metoprolol formulations, your doctor should be particularly careful with dosing.

Other medications that inhibit CYP2D6, including certain antihistamines, antipsychotics, and antifungals, can produce similar effects. The interaction applies equally to both tartrate and succinate, but the timing matters differently: with the extended-release form, the interaction produces a sustained elevation in drug levels rather than a brief spike, which can lead to prolonged low heart rate throughout the day. Make sure your prescriber has a complete list of your medications before switching.

Cost Differences Between the Two Formulations

Metoprolol tartrate has long been one of the cheapest prescription medications available. Succinate used to be significantly more expensive when it was still under patent, but generic versions have brought the price down substantially. A study comparing real-world expenditures found that total health care costs for patients on tartrate versus succinate were essentially the same, with no statistically significant difference in overall spending.¹⁶ Prescription drug costs were slightly higher for succinate users, about 6%, but this modest difference may be offset by the clinical and adherence benefits.

That said, insurance formularies vary. Some plans still tier the two differently, and your copay for one may be higher than the other. Before your doctor sends a new prescription, ask your pharmacy to run a price check on the succinate version at your specific dose. Generic metoprolol succinate is widely available and often costs under $15 for a month’s supply at most pharmacies, though this can vary.

Situations Where You Might Stay on Tartrate

Not everyone needs to switch. If you have straightforward high blood pressure, you are reliably taking tartrate twice a day without missed doses, your blood pressure is well controlled, and your insurance covers tartrate at a lower cost, there may be no compelling reason to change. The tartrate version has decades of clinical experience behind it and works well for many people.

Additionally, in some clinical settings where rapid dose adjustments are needed, such as acute atrial fibrillation rate control in a hospital or perioperative beta-blockade, tartrate is often preferred precisely because it is immediate-release. The shorter action lets clinicians titrate the dose more quickly and stop the effect sooner if problems arise. Succinate’s long, slow release makes it less suitable for situations where you need flexibility.

Some patients on very low doses, such as 12.5 mg of tartrate twice daily, may have no exact succinate equivalent since the smallest succinate tablet is 25 mg. In those cases, staying on tartrate or splitting the approach differently may make more sense. Your pharmacist and prescriber can work out the best option for your particular dose.

Nasogastric Tube and Swallowing Difficulties

If you have trouble swallowing pills or receive medications through a feeding tube, the choice between tartrate and succinate matters in a different way. Tartrate tablets can be crushed and given through a tube without changing how the drug works. Succinate tablets cannot be crushed without destroying the controlled-release mechanism. A study comparing both formulations through nasogastric tube administration found that the crushed succinate form was substantially less effective, with the lowest efficacy of all tested routes, while oral succinate had the highest.¹⁷ For patients on tube feeds, tartrate is the better-supported option unless a liquid or alternative formulation is available.